GleamWall
中文EN

ARGX ARGENX SE IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1697862 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY89.9%
TTM net income YoY55.1%
TTM EPS YoY53.1%
Revenue 3-yr CAGR118.0%
Net income 3-yr CAGR—

Margins

Gross margin89.1%
Operating margin25.4%
Net margin31.1%
FCF margin16.4%
EBITDA margin—

Returns

ROE20.2%
ROA17.4%
ROIC (approx.)26.9%
Asset turnover0.56x

Leverage & solvency

Liabilities / assets15.7%
Debt / equity0.00x
Current ratio5.23x
Interest coverage258.16x

Cash quality & payout

Operating cash flow / net income0.53x
Accruals ratio8.2%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2022Q22022-06-30
Income statement
Revenue$96.00M
Net income—
EPS (diluted)—
Balance sheet
Cash & equivalents$1.37B
Receivables$112.39M
Inventory$135.71M
Current assets$2.93B
PP&E, netmay include right-of-use assets (IFRS)$14.24M
Intangibles$171.29M
Total assets$3.25B
Current liabilities$264.60M
Total liabilities$279.02M
Shareholders' equity$2.97B
Shares outstanding55.06M
Cash flow statement
Operating cash flow—

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.